Effects of Roux-en-Y gastric bypass on circulating follistatin, activin A, and peripheral ActRIIB signaling in humans with obesity and type 2 diabetes

Effects of Roux-en-Y gastric bypass on circulating follistatin, activin A, and peripheral ActRIIB signaling in humans with obesity and type 2 diabetes

1.Schauer PR, Mingrone G, Ikramuddin S, Wolfe B. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care. 2016;39:902–11.CAS 
PubMed 
PubMed Central 

Google Scholar 
2.Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376:641–51.PubMed 
PubMed Central 

Google Scholar 
3.Albers PH, Bojsen-Moller KN, Dirksen C, Serup AK, Kristensen DE, Frystyk J, et al. Enhanced insulin signaling in human skeletal muscle and adipose tissue following gastric bypass surgery. Am J Physiol Regul Integr Comp Physiol. 2015;309:R510–24.CAS 
PubMed 

Google Scholar 
4.Bojsen-Moller KN, Dirksen C, Jorgensen NB, Jacobsen SH, Serup AK, Albers PH, et al. Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass. Diabetes. 2014;63:1725–37.PubMed 

Google Scholar 
5.Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010;59:3049–57.CAS 
PubMed 
PubMed Central 

Google Scholar 
6.Clemmensen C, Muller TD, Woods SC, Berthoud HR, Seeley RJ, Tschop MH. Gut-Brain cross-talk in metabolic control. Cell. 2017;168:758–74.CAS 
PubMed 
PubMed Central 

Google Scholar 
7.Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A, Rodino-Klapac LR, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1:6ra15.PubMed 
PubMed Central 

Google Scholar 
8.Mendell JR, Sahenk Z, Al-Zaidy S, Rodino-Klapac LR, Lowes LP, Alfano LN, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017;25:870–9.CAS 
PubMed 
PubMed Central 

Google Scholar 
9.Sepulveda PV, Lamon S, Hagg A, Thomson RE, Winbanks CE, Qian H, et al. Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy. Sci Rep. 2015;5:17535.CAS 
PubMed 
PubMed Central 

Google Scholar 
10.Garito T, Roubenoff R, Hompesch M, Morrow L, Gomez K, Rooks D, et al. Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals. Diabetes Obes Metab. 2018;20:94–102.CAS 
PubMed 

Google Scholar 
11.Han X, Moller LLV, De Groote E, Bojsen-Moller KN, Davey J, Henriquez-Olguin C, et al. Mechanisms involved in follistatin-induced hypertrophy and increased insulin action in skeletal muscle. J Cachexia Sarcopenia Muscle. 2019;10:1241–57.PubMed 

Google Scholar 
12.Hansen JS, Rutti S, Arous C, Clemmesen JO, Secher NH, Drescher A, et al. Circulating follistatin Is liver-derived and regulated by the glucagon-to-insulin ratio. J Clin Endocrinol Metab. 2016;101:550–60.CAS 
PubMed 

Google Scholar 
13.Latres E, Mastaitis J, Fury W, Miloscio L, Trejos J, Pangilinan J, et al. Activin A more prominently regulates muscle mass in primates than does GDF8. Nat Commun. 2017;8:15153.PubMed 
PubMed Central 

Google Scholar 
14.Han HQ, Zhou X, Mitch WE, Goldberg AL. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45:2333–47.CAS 
PubMed 

Google Scholar 
15.Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, et al. Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol. 2004;270:19–30.CAS 
PubMed 

Google Scholar 
16.Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, et al. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice. FASEB J. 2008;22:477–87.CAS 
PubMed 

Google Scholar 
17.Winbanks CE, Weeks KL, Thomson RE, Sepulveda PV, Beyer C, Qian H, et al. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. J Cell Biol. 2012;197:997–1008.CAS 
PubMed 
PubMed Central 

Google Scholar 
18.Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG, et al. Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study. J Am Geriatr Soc. 2017;65:1988–95.PubMed 

Google Scholar 
19.Braga M, Reddy ST, Vergnes L, Pervin S, Grijalva V, Stout D, et al. Follistatin promotes adipocyte differentiation, browning, and energy metabolism. J Lipid Res. 2014;55:375–84.CAS 
PubMed 
PubMed Central 

Google Scholar 
20.Singh R, Braga M, Reddy ST, Lee SJ, Parveen M, Grijalva V, et al. Follistatin targets distinct pathways to promote brown adipocyte characteristics in brown and white adipose tissues. Endocrinology. 2017;158:1217–30.CAS 
PubMed 
PubMed Central 

Google Scholar 
21.Hansen J, Rinnov A, Krogh-Madsen R, Fischer CP, Andreasen AS, Berg RM, et al. Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation. Diabetes Metab Res Rev. 2013;29:463–72.CAS 
PubMed 

Google Scholar 
22.Teede H, Ng S, Hedger M, Moran L. Follistatin and activins in polycystic ovary syndrome: relationship to metabolic and hormonal markers. Metab Clin Exp. 2013;62:1394–400.CAS 
PubMed 

Google Scholar 
23.Yndestad A, Haukeland JW, Dahl TB, Bjoro K, Gladhaug IP, Berge C, et al. A complex role of activin A in non-alcoholic fatty liver disease. Am J Gastroenterol. 2009;104:2196–205.CAS 
PubMed 

Google Scholar 
24.Perakakis N, Mougios V, Fatouros I, Siopi A, Draganidis D, Peradze N, et al. Physiology of activins/follistatins: associations with metabolic and anthropometric variables and response to exercise. J Clin Endocrinol Metab. 2018;103:3890–9.PubMed 
PubMed Central 

Google Scholar 
25.Perakakis N, Kokkinos A, Peradze N, Tentolouris N, Ghaly W, Tsilingiris D, et al. Follistatins in glucose regulation in healthy and obese individuals. Diabetes Obes Metab. 2019;21:683–90.CAS 
PubMed 

Google Scholar 
26.Tao R, Wang C, Stohr O, Qiu W, Hu Y, Miao J, et al. Inactivating hepatic follistatin alleviates hyperglycemia. Nat Med. 2018;24:1058–69.CAS 
PubMed 
PubMed Central 

Google Scholar 
27.Zhang YQ, Kanzaki M, Shibata H, Kojima I. Regulation of the expression of follistatin in rat hepatocytes. Biochim Biophys Acta. 1997;1354:204–10.CAS 
PubMed 

Google Scholar 
28.Welinder C, Ekblad L. Coomassie staining as loading control in Western blot analysis. J Proteome Res. 2011;10:1416–9.CAS 
PubMed 

Google Scholar 
29.Perakakis N, Kokkinos A, Peradze N, Tentolouris N, Ghaly W, Tsilingiris D, et al. Metabolic regulation of activins in healthy individuals and in obese patients undergoing bariatric surgery. Diabetes Metab Res Rev. 2020;36:e3297.CAS 
PubMed 

Google Scholar 
30.Motevalli MS, Dalbo VJ, Attarzadeh RS, Rashidlamir A, Tucker PS, Scanlan AT. The effect of rate of weight reduction on serum myostatin and follistatin concentrations in competitive wrestlers. Int J Sports Physiol Perform. 2015;10:139–46.PubMed 

Google Scholar 
31.Sylow L, Vind BF, Kruse R, Moller PM, Wojtaszewski JFP, Richter EA, et al. Circulating follistatin and activin A and their regulation by insulin in obesity and type 2 diabetes. J Clin Endocrinol Metab. 2020;105:1343–54.
Google Scholar 
32.Sakamoto Y, Shintani Y, Harada K, Abe M, Shitsukawa K, Saito S. Determination of free follistatin levels in sera of normal subjects and patients with various diseases. Eur J Endocrinol. 1996;135:345–51.CAS 
PubMed 

Google Scholar 
33.Shimonaka M, Inouye S, Shimasaki S, Ling N. Follistatin binds to both activin and inhibin through the common subunit. Endocrinology. 1991;128:3313–5.CAS 
PubMed 

Google Scholar 
34.Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell. 2005;9:535–43.CAS 
PubMed 

Google Scholar 
35.McConnell DS, Wang Q, Sluss PM, Bolf N, Khoury RH, Schneyer AL, et al. A two-site chemiluminescent assay for activin-free follistatin reveals that most follistatin circulating in men and normal cycling women is in an activin-bound state. J Clin Endocrinol Metab. 1998;83:851–8.CAS 
PubMed 

Google Scholar 
36.Gancheva S, Ouni M, Jelenik T, Koliaki C, Szendroedi J, Toledo FGS, et al. Dynamic changes of muscle insulin sensitivity after metabolic surgery. Nat Commun. 2019;10:4179.PubMed 
PubMed Central 

Google Scholar 
37.Hoffstedt J, Andersson DP, Eriksson Hogling D, Theorell J, Naslund E, Thorell A, et al. Long-term protective changes in adipose tissue after gastric bypass. Diabetes Care. 2017;40:77–84.CAS 
PubMed 

Google Scholar 
38.Cai H, Dong LQ, Liu F. Recent advances in adipose mTOR signaling and function: therapeutic prospects. Trends Pharmacol Sci. 2016;37:303–17.CAS 
PubMed 

Google Scholar 
39.Flanagan JN, Linder K, Mejhert N, Dungner E, Wahlen K, Decaunes P, et al. Role of follistatin in promoting adipogenesis in women. J Clin Endocrinol Metab. 2009;94:3003–9.CAS 
PubMed 
PubMed Central 

Google Scholar 
40.Inouye S, Guo Y, DePaolo L, Shimonaka M, Ling N, Shimasaki S. Recombinant expression of human follistatin with 315 and 288 amino acids: chemical and biological comparison with native porcine follistatin. Endocrinology. 1991;129:815–22.CAS 
PubMed 

Google Scholar 
41.Sidis Y, Mukherjee A, Keutmann H, Delbaere A, Sadatsuki M, Schneyer A. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins. Endocrinology. 2006;147:3586–97.CAS 
PubMed 

Google Scholar 
42.Kimura F, Sidis Y, Bonomi L, Xia Y, Schneyer A. The follistatin-288 isoform alone is sufficient for survival but not for normal fertility in mice. Endocrinology. 2010;151:1310–9.CAS 
PubMed 

Google Scholar 

Via Source link